Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/1477-7819-10-173.

Title:
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? | World Journal of Surgical Oncology
Description:
Esophageal cancer is the eighth most common cancer worldwide, and especially in some areas of China is the fourth most common cause of death and is of squamous cell carcinoma (SCC) histology in >90% of cases. Surgery alone was the mainstay of therapeutic intervention in the past, but high rates of local and systemic failure have prompted investigation into multidisciplinary management. In this review, we discuss the key issues raised by the recent availability of esophageal SCC treatment with the addition of chemotherapy, radiotherapy, and chemoradiotherapy to the surgical management of resectable disease and discuss how clinical trials and meta-analysis inform current clinical practice. None of the randomized trials that compared neoadjuvant radiotherapy or chemotherapy with surgery alone in esophageal SCC has demonstrated an increase in overall survival in those patients treated with neoadjuvant radiotherapy or chemotherapy. Neoadjuvant chemoradiotherapy has been accepted recently for esophageal cancer because such a regimen offers great opportunity for margin negative resection, improved loco-regional control and increased survival. The majority of the available evidence currently reveals that only selected locally advanced esophageal SCC are more likely to benefit from the adjuvant therapy. The focus of future trials should be on identification of the optimum regimen and should aim to minimize treatment toxicities and effect on quality of life, as well as attempt to identify and select those patients most likely to benefit from specific treatment options.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {šŸ“š}

  • Science
  • Insurance
  • Health & Fitness

Content Management System {šŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {šŸ’ø}

We can't tell how the site generates income.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {šŸ”}

esophageal, surgery, neoadjuvant, patients, cancer, article, pubmed, adjuvant, google, scholar, randomized, scc, carcinoma, crt, survival, trials, squamous, cell, trial, cas, chemotherapy, study, treatment, compared, radiotherapy, esophagus, benefit, therapy, oncol, preoperative, surg, clinical, metaanalysis, year, cisplatin, versus, resectable, chemoradiotherapy, phase, iii, table, significant, surgical, addition, colleagues, controlled, results, oncology, disease, demonstrated,

Topics {āœ’ļø}

current loco-regional control open access article article download pdf resectable oesophageal carcinoma improved loco-regional control squamous cell carcinoma squamous cell cancer squamous-cell cancer tumor-specific markers predictive org/professionals/physician_gls/f_guidelines large-sample randomized trials small-sample retrospective study phase iii study treatment-related mortality rates postoperative radiation therapy network meta-analysis localized squamous carcinoma phase iii trial phase iii trials significant treatment-related mortality limited sample size v325 study group privacy choices/manage cookies cell cycle synchronization recent meta-analysis demonstrated disease-free survival rate locally advanced egi pre-operative radiotherapy surgical oncology aims full access resectable esophageal carcinoma multicenter controlled trial operable esophageal carcinoma resectable esophageal cancer thoracic esophageal cancer advanced gastric cancer randomized controlled study localized esophageal cancer early esophageal cancer multiple smoking-related multicenter randomized trial neoadjuvant chemoradiation therapy medical oncology stage ii patients viable cancer cells natl cancer inst reduce cancer disparities cancer chemother pharmacol clinical complete response radiation oncology

Questions {ā“}

  • Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
  • Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
  • Siewert JR, Ott K: Are squamous and adenocarcinomas of the esophagus the same disease?

Schema {šŸ—ŗļø}

WebPage:
      mainEntity:
         headline:Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
         description:Esophageal cancer is the eighth most common cancer worldwide, and especially in some areas of China is the fourth most common cause of death and is of squamous cell carcinoma (SCC) histology in >90% of cases. Surgery alone was the mainstay of therapeutic intervention in the past, but high rates of local and systemic failure have prompted investigation into multidisciplinary management. In this review, we discuss the key issues raised by the recent availability of esophageal SCC treatment with the addition of chemotherapy, radiotherapy, and chemoradiotherapy to the surgical management of resectable disease and discuss how clinical trials and meta-analysis inform current clinical practice. None of the randomized trials that compared neoadjuvant radiotherapy or chemotherapy with surgery alone in esophageal SCC has demonstrated an increase in overall survival in those patients treated with neoadjuvant radiotherapy or chemotherapy. Neoadjuvant chemoradiotherapy has been accepted recently for esophageal cancer because such a regimen offers great opportunity for margin negative resection, improved loco-regional control and increased survival. The majority of the available evidence currently reveals that only selected locally advanced esophageal SCC are more likely to benefit from the adjuvant therapy. The focus of future trials should be on identification of the optimum regimen and should aim to minimize treatment toxicities and effect on quality of life, as well as attempt to identify and select those patients most likely to benefit from specific treatment options.
         datePublished:2012-08-25T00:00:00Z
         dateModified:2012-08-25T00:00:00Z
         pageStart:1
         pageEnd:8
         license:https://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1477-7819-10-173
         keywords:
            Esophageal cancer
            Squamous cell carcinoma
            Neoadjuvant therapy
            Adjuvant therapy
            Chemotherapy
            Radiotherapy
            Chemoradiotherapy
            Surgical Oncology
         image:
         isPartOf:
            name:World Journal of Surgical Oncology
            issn:
               1477-7819
            volumeNumber:10
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yaping Xu
               affiliation:
                     name:Zhejiang Cancer Hospital
                     address:
                        name:Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xinmin Yu
               affiliation:
                     name:Zhejiang Cancer Hospital
                     address:
                        name:Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Qixun Chen
               affiliation:
                     name:Zhejiang Cancer Hospital
                     address:
                        name:Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Weimin Mao
               affiliation:
                     name:Zhejiang Cancer Hospital
                     address:
                        name:Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
      description:Esophageal cancer is the eighth most common cancer worldwide, and especially in some areas of China is the fourth most common cause of death and is of squamous cell carcinoma (SCC) histology in >90% of cases. Surgery alone was the mainstay of therapeutic intervention in the past, but high rates of local and systemic failure have prompted investigation into multidisciplinary management. In this review, we discuss the key issues raised by the recent availability of esophageal SCC treatment with the addition of chemotherapy, radiotherapy, and chemoradiotherapy to the surgical management of resectable disease and discuss how clinical trials and meta-analysis inform current clinical practice. None of the randomized trials that compared neoadjuvant radiotherapy or chemotherapy with surgery alone in esophageal SCC has demonstrated an increase in overall survival in those patients treated with neoadjuvant radiotherapy or chemotherapy. Neoadjuvant chemoradiotherapy has been accepted recently for esophageal cancer because such a regimen offers great opportunity for margin negative resection, improved loco-regional control and increased survival. The majority of the available evidence currently reveals that only selected locally advanced esophageal SCC are more likely to benefit from the adjuvant therapy. The focus of future trials should be on identification of the optimum regimen and should aim to minimize treatment toxicities and effect on quality of life, as well as attempt to identify and select those patients most likely to benefit from specific treatment options.
      datePublished:2012-08-25T00:00:00Z
      dateModified:2012-08-25T00:00:00Z
      pageStart:1
      pageEnd:8
      license:https://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1477-7819-10-173
      keywords:
         Esophageal cancer
         Squamous cell carcinoma
         Neoadjuvant therapy
         Adjuvant therapy
         Chemotherapy
         Radiotherapy
         Chemoradiotherapy
         Surgical Oncology
      image:
      isPartOf:
         name:World Journal of Surgical Oncology
         issn:
            1477-7819
         volumeNumber:10
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yaping Xu
            affiliation:
                  name:Zhejiang Cancer Hospital
                  address:
                     name:Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xinmin Yu
            affiliation:
                  name:Zhejiang Cancer Hospital
                  address:
                     name:Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Qixun Chen
            affiliation:
                  name:Zhejiang Cancer Hospital
                  address:
                     name:Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Weimin Mao
            affiliation:
                  name:Zhejiang Cancer Hospital
                  address:
                     name:Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:World Journal of Surgical Oncology
      issn:
         1477-7819
      volumeNumber:10
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Zhejiang Cancer Hospital
      address:
         name:Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
         type:PostalAddress
      name:Zhejiang Cancer Hospital
      address:
         name:Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
         type:PostalAddress
      name:Zhejiang Cancer Hospital
      address:
         name:Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
         type:PostalAddress
      name:Zhejiang Cancer Hospital
      address:
         name:Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yaping Xu
      affiliation:
            name:Zhejiang Cancer Hospital
            address:
               name:Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Xinmin Yu
      affiliation:
            name:Zhejiang Cancer Hospital
            address:
               name:Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Qixun Chen
      affiliation:
            name:Zhejiang Cancer Hospital
            address:
               name:Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Weimin Mao
      affiliation:
            name:Zhejiang Cancer Hospital
            address:
               name:Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
      name:Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
      name:Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
      name:Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China

External Links {šŸ”—}(181)

Analytics and Tracking {šŸ“Š}

  • Google Tag Manager

Libraries {šŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {šŸ“¦}

  • Crossref

4.8s.